Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys

Transpl Immunol. 2013 Dec;29(1-4):88-98. doi: 10.1016/j.trim.2013.10.002. Epub 2013 Oct 9.

Abstract

Repopulation of memory T cells (Tmem) in allograft recipients after lymphodepletion is a major barrier to transplant tolerance induction. Ineffective depletion of naïve T cells (Tn) and Tmem may predispose to repopulation of Tmem after transplantation. Cynomolgus macaque monkeys given heart allografts were lymphodepleted using Alemtuzumab (Campath-1H; anti-CD52). Peripheral blood (PB) and lymph nodes (LN) were analyzed for CD95(-) (Tn) and CD95(+) cells (Tmem), one day, one month and up to three months after Alemtuzumab infusion. CD52 expression, susceptibility to Alemtuzumab cytotoxicity and pro-apoptotic caspase-3 were evaluated in Tn and Tmem. In vivo, Alemtuzumab induction profoundly depleted lymphocytes in PB (99% reduction) but exerted a lesser effect in LN (70% reduction), with similar depletion of Tn and Tmem subsets. After transplantation, Tmem comprised the majority of lymphocytes in PB and LN. In vitro, LN T cells were more resistant to Alemtuzumab-mediated cytotoxicity than PB lymphocytes. CD4(+) Tn and Tmem were equally susceptible to Alemtuzumab-mediated cytotoxicity, whereas CD8(+) Tn were more resistant than CD8(+) Tmem. However, no significant differences in CD52 expression between lymphocyte subsets in PB and LN were observed. Caspase-3 expression was higher in PB than LN T cells. CD4(+) and CD8(+) Tn expressed lower levels of Caspase-3 than Tmem, in both PB and LN. Thus, after Alemtuzumab infusion, residual Tn in secondary lymphoid tissue may predispose to rapid recovery of Tmem in allograft recipients.

Keywords: ATG; Alemtuzumab; LN; Lymph node; MFI; Memory T cell; NHP; Naïve T cell; Non-human primate; PBMC; Tmem; Tn; Transplantation; anti-thymocyte globulin; lymph node(s); mean fluorescence intensity; memory T cell(s); naïve T cell(s); non-human primate; peripheral blood mononuclear cells.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alemtuzumab
  • Allografts
  • Animals
  • Antibodies, Monoclonal, Humanized / pharmacology*
  • Antineoplastic Agents / pharmacology*
  • CD4-Positive T-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / pathology
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / pathology
  • Caspase 3 / immunology
  • Heart Transplantation*
  • Lymphocyte Depletion*
  • Lymphoid Tissue / immunology*
  • Lymphoid Tissue / pathology
  • Macaca fascicularis
  • Memory, Short-Term / drug effects*
  • fas Receptor / immunology

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • fas Receptor
  • Alemtuzumab
  • Caspase 3